Vinayak G. Wagaskar, MBBS, explains the “obesity paradox”—improved survival outcomes in patients with a high body mass index (BMI)—that has been observed in patients with genitourinary malignancies, including prostate cancer.
Wagaskar also highlights a study presented at the 2021 European Association of Urology Congress which reported evidence of the obesity paradox in patients with metastatic castration-resistant prostate cancer (mCRPC). Specifically, an analysis of nearly 1600 patients with mCRPC enrolled across three phase 3 trials showed that the overall survival rate at 36 months was about 30% in obese patients (BMI >30) compared with 20% in overweight (25< BMI <30) and normal weight (20< BMI <25) patients.
Wagaskar is an instructor of urology at Mount Sinai in New York City.
Study finds disparities in management of mCSPC
April 17th 2024“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.